FDA approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
ABBVIE will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer. The transaction is expected to close in second-quarter of this year. Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 that is expressed in more […]
GEISINGER HEALTH SYSTEM announced that 100,000 recruits have signed up for the health system’s major biobank and DNA sequencing study known as the MyCode Community Health Initiative. Launched in January 2014 in collaboration with the Regeneron Genetics Center, the MyCode Community Health Initiative originally set out to recruit 100,000 study participants. That target, however, was […]
THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center raised nearly $1.2 million for cancer research at its fourth annual Chuckstrong Tailgate Gala. Hosted by the Indianapolis Colts and head coach Chuck Pagano at the Indiana Farm Bureau Football Center, the gala raised the funds through corporate sponsorships, live and silent auctions, and the annual […]
ABBVIE and argenx, a clinical-stage biopharmaceutical company, will collaborate to develop and commercialize ARGX-115, Argenx’s preclinical-stage human antibody program targeting the immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells. “ARGX-115 has been developed in collaboration with an outstanding team of academics at the de Duve Institute / Université Catholique de […]
THE WISTAR INSTITUTE and Cormorant Pharmaceuticals AB, a Swedish biopharmaceutical company specializing in cancer drug development, formed a partnership involving Cormorant’s novel drug HuMax-IL8, which is undergoing a phase I trial at NCI. “Wistar’s biomarker analysis of the tumor samples will be instrumental in determining the effects of HuMax-IL8 on tumor immunosuppression,” said Maarten de […]
MD ANDERSON CANCER CENTER and Summit Medical Group in New Jersey announced the launch of their partnership to create the Summit Medical Group MD Anderson Cancer Center. An extension of MD Anderson Cancer Center at Cooper in Camden, N.J., Summit Medical Group will now be clinically and operationally integrated with MD Anderson Cancer Center in […]
ALBERT EINSTEIN COLLEGE OF MEDICINE entered into a research agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop innovative cancer therapies. The collaboration is the first between Einstein and a pharmaceutical company based in China. Jiangsu Hengrui Medicine, established in 1970, is a fully integrated pharmaceutical company with annual net sales of over $1.2 billion. […]
KIDS V CANCER launched the Compassionate Use Navigator for the pediatric oncology community that provides up-to-date information on the compassionate use application process. The Compassionate Use Navigator provides: an option for physicians to request help from Compassionate Use Navigator staff in completing a compassionate use application; step-by-step instructions on how to apply for compassionate use, […]
NATIONAL COMPREHENSIVE CANCER NETWORK published patient education materials for diffuse large b-cell, follicular, mantle cell, and peripheral t-cell lymphomas. The NCCN Guidelines for Patients and NCCN Quick Guide series for Non-Hodgkin’s lymphomas are available free of charge, and are sponsored by the Leukemia & Lymphoma Society. NCCN Guidelines for Patients, translations of the NCCN Clinical […]
